Risk Factors of Venous Thromboembolism in Noncritically Ill Patients Hospitalized for Acute COVID-19 Pneumonia Receiving Prophylactic-Dose Anticoagulation

Background: Therapeutic/intermediate-dose heparin reduces the risk of thromboembolic events but increases the risk of major bleeding in patients hospitalized for acute COVID-19 pneumonia. Objectives: To prospectively assess the incidence of objectively proven venous thromboembolism (VTE) and identif...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Viruses Ročník 14; číslo 4; s. 737
Hlavní autori:	Poletto, Francesco, Spiezia, Luca, Simion, Chiara, Campello, Elena, Dalla Valle, Fabio, Tormene, Daniela, Camporese, Giuseppe, Simioni, Paolo
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	Switzerland MDPI AG 31.03.2022 MDPI
Predmet:	Aged Anticoagulants - therapeutic use Bleeding Blood Blood platelets Body mass index Cardiovascular disease Contraindications Coronaviruses COVID-19 COVID-19 - epidemiology Creatinine Data collection Diabetes Hemoglobin Heparin Heparin - adverse effects Hospitalization Hospitals Humans Hypertension Kidney diseases Laboratories Obesity Obesity - complications Patients Pneumonia prophylactic-dose anticoagulation Retrospective Studies Risk Factors Sepsis Severe acute respiratory syndrome coronavirus 2 Thromboembolism Thrombosis venous thromboembolism Venous Thromboembolism - drug therapy Venous Thromboembolism - epidemiology Venous Thromboembolism - prevention & control Italy COVID-19 prophylactic-dose anticoagulation venous thromboembolism
ISSN:	1999-4915, 1999-4915
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!